{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:10:29Z","timestamp":1784275829009,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amryt Pharmaceuticals Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metreleptin, a recombinant analog of human leptin, is an approved therapy, adjunct to diet, to treat the metabolic complications of leptin deficiency in patients with lipodystrophy \u2013 a group of rare diseases characterized by a paucity of adipose tissue. MEASuRE (Metreleptin Effectiveness And Safety Registry) is a post-authorization, voluntary registry that gathers long-term safety and effectiveness data on metreleptin. Here, we present the aims and evolution of MEASuRE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEASuRE was established to collect data from patients receiving commercially supplied metreleptin in the United States (US) and European Union (EU). MEASuRE aims to determine the incidence and severity of safety events and describe the clinical characteristics and therapeutic outcomes in the metreleptin-treated population. A key feature of MEASuRE is that it accumulates data from different sources to meet post-authorization objectives. US data are received directly from treating physicians via a contract research organization-mediated electronic data capture system. In the EU, data are received via the European Registry of Lipodystrophies managed by the European Consortium of Lipodystrophies (ECLip), a platform established by researchers and physicians to advance the knowledge of lipodystrophy. MEASuRE complies with applicable regulatory requirements governing privacy, and the storage, management, and access of data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Leveraging processes, infrastructure, and data from the ECLip registry presented several challenges that were addressed during MEASuRE\u2019s development, including the expansion of the ECLip registry to accommodate MEASuRE-specific data elements, extensive data matching processes to ensure data consistency regardless of source, and rigorous data validation following the amalgamation of global data. Through the support of ECLip, MEASuRE is now a fully operational registry with the capacity for gathering and integrating standardized US- and EU-derived data. As of 31st October 2022, 15 US and four EU sites have participated in the MEASuRE, enrolling 85 patients globally.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our experiences show that a post-authorization product registry can be successfully integrated into an existing patient registry. We propose that, through collaboration with existing registries and use of their established resources, patient enrolment timelines and data collection for new registries can be expedited. The learnings presented here may be applicable to other registries with similar objectives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02325674; Registered 25 December 2014 - Retrospectively registered\u2019. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02325674\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02325674<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02714-5","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T09:04:27Z","timestamp":1685091867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-2913","authenticated-orcid":false,"given":"Morey W","family":"Haymond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-7851","authenticated-orcid":false,"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Balser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-3405","authenticated-orcid":false,"given":"James H","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Louzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-664X","authenticated-orcid":false,"given":"Julia","family":"von Schnurbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-8430","authenticated-orcid":false,"given":"Martin","family":"Wabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MEASuRE group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"12","key":"2714_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of Lipodystrophy Syndromes: a Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2714_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"2714_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","volume":"42","author":"D Araujo-Vilar","year":"2019","unstructured":"Araujo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2019;42(1):61\u201373.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2714_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","volume":"46","author":"M Lightbourne","year":"2017","unstructured":"Lightbourne M, Brown RJ. Genetics of Lipodystrophy. Endocrinol Metab Clin North Am. 2017;46(2):539\u201354.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"2714_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","volume":"18","author":"B Akinci","year":"2018","unstructured":"Akinci B, Meral R, Oral EA. Phenotypic and genetic characteristics of Lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities. Curr Diab Rep. 2018;18(12):143.","journal-title":"Curr Diab Rep"},{"issue":"11","key":"2714_CR6","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"2714_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DMSO.S130810","volume":"10","author":"E Chiquette","year":"2017","unstructured":"Chiquette E, Oral EA, Garg A, Araujo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375\u201383.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"2714_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/db19-0447","volume":"69","author":"C Gonzaga-Jauregui","year":"2020","unstructured":"Gonzaga-Jauregui C, Ge W, Staples J, Van Hout C, Yadav A, Colonie R, et al. Clinical and molecular prevalence of Lipodystrophy in an unascertained large clinical care cohort. Diabetes. 2020;69(2):249\u201358.","journal-title":"Diabetes"},{"issue":"11","key":"2714_CR9","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/jc.2018-02730","volume":"104","author":"B Akinci","year":"2019","unstructured":"Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, et al. Comorbidities and survival in patients with lipodystrophy: an International Chart Review study. J Clin Endocrinol Metab. 2019;104(11):5120\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9\u201310","key":"2714_CR10","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/jocn.14342","volume":"27","author":"C Adams","year":"2018","unstructured":"Adams C, Stears A, Savage D, Deaton C. We\u2019re stuck with what we\u2019ve got\u201d: the impact of lipodystrophy on body image. J Clin Nurs. 2018;27(9\u201310):1958\u201368.","journal-title":"J Clin Nurs"},{"issue":"1","key":"2714_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s41687-022-00486-3","volume":"6","author":"SA Martin","year":"2022","unstructured":"Martin SA, Sanchez RJ, Olayinka-Amao O, Harris C, Fehnel S. Qualitative interviews in patients with lipodystrophy to assess the patient experience: evaluation of hunger and other symptoms. J Patient Rep Outcomes. 2022;6(1):84.","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"2714_CR12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1210\/clinem\/dgac079","volume":"107","author":"LT Fourman","year":"2022","unstructured":"Fourman LT, Grinspoon SK. Approach to the patient with Lipodystrophy. J Clin Endocrinol Metab. 2022;107(6):1714\u201326.","journal-title":"J Clin Endocrinol Metab"},{"key":"2714_CR13","doi-asserted-by":"publisher","unstructured":"Zammouri J, Vatier C, Capel E, Auclair M, Storey-London C, Bismuth E, et al. Molecular and Cellular Bases of Lipodystrophy Syndromes. Front Endocrinol (Lausanne). 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.803189.","DOI":"10.3389\/fendo.2021.803189"},{"key":"2714_CR14","unstructured":"Amryt Pharmaceuticals DAC. Myalept package insert 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125390s024lbl.pdf [accessed April [accessed April 2023].023]"},{"key":"2714_CR15","unstructured":"Amryt Pharmaceuticals DAC. Myalepta summary of product characteristics 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myalepta [accessed April [accessed April 2023].023]"},{"issue":"3","key":"2714_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","volume":"60","author":"RJ Brown","year":"2018","unstructured":"Brown RJ, Oral EA, Cochran E, Araujo-Vilar D, Savage DB, Long A, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60(3):479\u201389.","journal-title":"Endocrine"},{"issue":"3","key":"2714_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","volume":"64","author":"EA Oral","year":"2019","unstructured":"Oral EA, Gorden P, Cochran E, Araujo-Vilar D, Savage DB, Long A, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500\u201311.","journal-title":"Endocrine"},{"key":"2714_CR18","unstructured":"European Medicines Agency. Guideline on registry-based studies Amsterdam 2021 [updated 19 October 2022; cited 2022 19 October]. Available from: https:\/\/www.ema.europa.eu\/en\/guideline-registry-based-studies-0 [accessed April [accessed April 2023].023]"},{"issue":"9771","key":"2714_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(10)60680-0","volume":"377","author":"CB Forrest","year":"2011","unstructured":"Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet. 2011;377(9771):1057\u20139.","journal-title":"Lancet"},{"issue":"1","key":"2714_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cpt.1414","volume":"106","author":"CA Olmo","year":"2019","unstructured":"Olmo CA, McGettigan P, Kurz X. Barriers and Opportunities for Use of Patient Registries in Medicines Regulation. Clin Pharmacol Ther. 2019;106(1):39\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2714_CR21","first-page":"185","volume":"34","author":"V Boulanger","year":"2020","unstructured":"Boulanger V, Schlemmer M, Rossov S, Seebald A, Gavin P. Establishing patient registries for Rare Diseases: Rationale and Challenges. Pharmaceut Med. 2020;34(3):185\u201390.","journal-title":"Pharmaceut Med"},{"key":"2714_CR22","unstructured":"Gliklich RE, Dreyer NA, Leavy MB. Registries for Evaluating Patient Outcomes: A User\u2019s Guide [Internet]. 3rd edition 2014. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK208643\/ [accessed April [accessed April 2023].023]"},{"key":"2714_CR23","doi-asserted-by":"publisher","first-page":"832063","DOI":"10.3389\/fendo.2022.832063","volume":"13","author":"S Kolker","year":"2022","unstructured":"Kolker S, Gleich F, Mutze U, Opladen T. Rare disease registries are key to evidence-based Personalized Medicine: highlighting the european experience. Front Endocrinol (Lausanne). 2022;13:832063.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2714_CR24","doi-asserted-by":"publisher","first-page":"924648","DOI":"10.3389\/fphar.2022.924648","volume":"13","author":"CJ Jonker","year":"2022","unstructured":"Jonker CJ, Bakker E, Kurz X, Plueschke K. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022;13:924648.","journal-title":"Front Pharmacol"},{"key":"2714_CR25","unstructured":"Food and Drug Administration. Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry 2021 [Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm259809.htm [accessed April [accessed April 2023].023]"},{"key":"2714_CR26","unstructured":"Food and Drug Administration. Framework for FDA\u2019s Real-World Evidence Program 2018 [Available from: https:\/\/www.fda.gov\/media\/120060\/download, accessed April 2023]."},{"key":"2714_CR27","unstructured":"European Medicines Agency. Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force London 2017 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/patient-registry-initiative-strategy-mandate-cross-committee-task-force_en.pdf, accessed April 2023]."},{"key":"2714_CR28","unstructured":"European Consortium of Lipodystrophies (ECLip). Lipodystrophies 2019. Available from: https:\/\/www.eclip-web.org\/lipodystrophies\/ [accessed April [accessed April 2023].023]"},{"key":"2714_CR29","first-page":"209","volume":"253","author":"J Schaaf","year":"2018","unstructured":"Schaaf J, Kadioglu D, Goebel J, Behrendt CA, Roos M, van Enckevort D, et al. OSSE goes FAIR - implementation of the FAIR Data Principles for an Open-Source Registry for Rare Diseases. Stud Health Technol Inform. 2018;253:209\u201313.","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"2714_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-020-1295-y","volume":"15","author":"J von Schnurbein","year":"2020","unstructured":"von Schnurbein J, Adams C, Akinci B, Ceccarini G, D\u2019Apice MR, Gambineri A, et al. European lipodystrophy registry: background and structure. Orphanet J Rare Dis. 2020;15(1):17.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2714_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee ISoP","year":"2016","unstructured":"Public Policy Committee ISoP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2714_CR32","unstructured":"European Medicines Agency. ICH E6 (R2) Good clinical practice - Scientific guideline2002. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice-scientific-guideline [accessed April [accessed April 2023].023]"},{"issue":"20","key":"2714_CR33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"2714_CR34","unstructured":"ClinicalTrials.gov. History of Changes for Study: NCT02325674: MEASuRE: Metreleptin Effectiveness And Safety Registry (MEASuRE)2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/history\/NCT02325674 [accessed April [accessed April 2023].023]"},{"key":"2714_CR35","unstructured":"AstraZeneca, US FDA approves orphan drug MYALEPT\u2122 (metreleptin for injection). 2014. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2014\/us-fda-approved-myalept-lepti-deficiency-treatment-25022014.html#, accessed April 2023."},{"key":"2714_CR36","unstructured":"OSSE \u2013 Open Source Registry System for Rare. Diseases [cited 2022 15 November]. Available from: https:\/\/en.osse-register.de\/en\/; accesed January 2023."},{"key":"2714_CR37","unstructured":"Food and Drug Administration. Guidance for Industry: Part 11, Electronic Records; Electronic Signatures - Scope and Application 2003 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/part-11-electronic-records-electronic-signatures-scope-and-application; accessed April 2023."},{"issue":"11","key":"2714_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40264-019-00848-9","volume":"42","author":"P McGettigan","year":"2019","unstructured":"McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, et al. Patient registries: an underused resource for Medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf : Int J Med Toxicol drug experience. 2019;42(11):1343\u201351.","journal-title":"Drug Saf : Int J Med Toxicol drug experience"},{"key":"2714_CR39","unstructured":"European Medicines Agency. Scientific guidance on post-authorisation efficacy studies London 2015 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf; accessed April 2023]."},{"key":"2714_CR40","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VIII \u2013 Post-authorisation safety studies (Rev 3) 2017 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf; accessed April 2023]."},{"issue":"12","key":"2714_CR41","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/pds.4196","volume":"26","author":"JC Bouvy","year":"2017","unstructured":"Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in european post-marketing surveillance: a retrospective analysis of centrally approved products, 2005\u20132013. Pharmacoepidemiol Drug Saf. 2017;26(12):1442\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"2714_CR42","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/pds.4449","volume":"27","author":"A Pacurariu","year":"2018","unstructured":"Pacurariu A, Plueschke K, Olmo CA, Kurz X. Imposed registries within the european postmarketing surveillance system: extended analysis and lessons learned for regulators. Pharmacoepidemiol Drug Saf. 2018;27(7):823\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2714_CR43","unstructured":"European Medicines Agency. Initiative for patient registries \u2013 strategy and pilot phase2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/initiative-patient-registries-strategy-pilot-phase_en.pdf [accessed April [accessed April 2023].023]"},{"key":"2714_CR44","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.yjbinx.2020.100074","volume":"112S","author":"N Nicholson","year":"2020","unstructured":"Nicholson N, Perego A. Interoperability of population-based patient registries. J Biomed Inform. 2020;112S:100074.","journal-title":"J Biomed Inform"},{"key":"2714_CR45","unstructured":"European Medicines Agency. Patient Registries [Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/patient-registries [accessed April [accessed April 2023].023]"},{"key":"2714_CR46","doi-asserted-by":"publisher","first-page":"966081","DOI":"10.3389\/fphar.2022.966081","volume":"13","author":"M Mordenti","year":"2022","unstructured":"Mordenti M, Boarini M, D\u2019Alessandro F, Pedrini E, Locatelli M, Sangiorgi L. Remodeling an existing rare disease registry to be used in regulatory context: Lessons learned and recommendations. Front Pharmacol. 2022;13:966081.","journal-title":"Front Pharmacol"},{"key":"2714_CR47","unstructured":"Amryt Pharmaceuticals DAC. Myalepta summary of product characteristics 2022. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11184\/smpc [accessed April [accessed April 2023].023]"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02714-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T09:07:42Z","timestamp":1685092062000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02714-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02714-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MEASuRE was approved by the ethics committees of each of the participating centers. All patients provided informed consent for participation in MEASuRE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided informed consent for their data to be used in MEASuRE and its subsequent publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MWH chairs an advisory board for Amryt Pharmaceuticals Inc.DA-V has received fees for lectures from Amryt Pharma, for meeting registration, travel and\/or accommodation from Aegerion Pharmaceuticals and Amryt Pharma and has received institutional research funding from Aegerion Pharmaceuticals.JB is a contractor for Amryt Pharmaceuticals Inc.JHL has no conflicts to declare.RL is an employee of Amryt Pharmaceuticals DAC.CM has no conflicts to declare.JvS received honoraria for speaking engagements from Amryt Pharmaceuticals in 2018 and 2022.MW has received honoraria for speaking engagements and advisory board participation from Amryt Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}